JP2016512504A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512504A5 JP2016512504A5 JP2016500921A JP2016500921A JP2016512504A5 JP 2016512504 A5 JP2016512504 A5 JP 2016512504A5 JP 2016500921 A JP2016500921 A JP 2016500921A JP 2016500921 A JP2016500921 A JP 2016500921A JP 2016512504 A5 JP2016512504 A5 JP 2016512504A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- substituted
- phenyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 44
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000004122 cyclic group Chemical group 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 0 CC(C*)c1ccccn1 Chemical compound CC(C*)c1ccccn1 0.000 description 4
- JAWZAONCXMJLFT-UHFFFAOYSA-N CCCc1ccncc1 Chemical compound CCCc1ccncc1 JAWZAONCXMJLFT-UHFFFAOYSA-N 0.000 description 1
- ZQBNNLNJNVYINU-UHFFFAOYSA-N CSC(c1cnccn1)S Chemical compound CSC(c1cnccn1)S ZQBNNLNJNVYINU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775742P | 2013-03-11 | 2013-03-11 | |
| US61/775,742 | 2013-03-11 | ||
| PCT/US2014/022238 WO2014143607A1 (en) | 2013-03-11 | 2014-03-10 | Pyrrolopyridazines as potassium ion channel inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512504A JP2016512504A (ja) | 2016-04-28 |
| JP2016512504A5 true JP2016512504A5 (cg-RX-API-DMAC7.html) | 2017-04-13 |
| JP6386527B2 JP6386527B2 (ja) | 2018-09-05 |
Family
ID=50382739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016500921A Expired - Fee Related JP6386527B2 (ja) | 2013-03-11 | 2014-03-10 | カリウムイオンチャネル阻害剤としてのピロロピリダジン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9458164B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2970295B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6386527B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105008366B (cg-RX-API-DMAC7.html) |
| ES (1) | ES2616026T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014143607A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9403834B2 (en) | 2013-03-11 | 2016-08-02 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| WO2014143609A1 (en) | 2013-03-11 | 2014-09-18 | Bristol-Myers Squibb Company | Isoquinolines as potassium ion channel inhibitors |
| AU2019213836A1 (en) * | 2018-01-30 | 2020-09-10 | Buckman Laboratories International, Inc. | Synergistic combinations of monochloramine and organic acid, and methods of using the same for microbial control |
| EP4651951A1 (en) * | 2023-01-19 | 2025-11-26 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| WO2025008227A1 (en) | 2023-07-05 | 2025-01-09 | Basf Se | Substituted pyridyl/pyrazinyl dihydropyrrolotriazine compounds for combatting phytopath-ogenic fungi |
| WO2025008226A1 (en) | 2023-07-05 | 2025-01-09 | Basf Se | Substituted quinolyl/quinoxalyl dihydropyrrolotriazine compounds for combatting phyto-pathogenic fungi |
| WO2025077671A1 (zh) * | 2023-10-09 | 2025-04-17 | 浙江海正药业股份有限公司 | 多取代芳基类衍生物及其制备方法和用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| NZ508118A (en) | 1998-07-06 | 2003-07-25 | Bristol Myers Squibb Co | Heteroaryl substituted biphenyl sulfonamides useful as dual angiotensin endothelin receptor antogonists |
| PL204437B1 (pl) * | 1999-05-21 | 2010-01-29 | Bristol Myers Squibb Co | Pochodna pirolotriazyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie |
| HRP20030485A2 (en) * | 2000-11-17 | 2004-08-31 | Bristol Myers Squibb Co | METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS |
| US6900208B2 (en) * | 2002-03-28 | 2005-05-31 | Bristol Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| TW200420565A (en) * | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| WO2004099213A2 (en) * | 2003-05-07 | 2004-11-18 | Pharmacia & Upjohn Company Llc | Pyrrolo (1,2-b) pyridazine compounds and their use as crf-1 receptor antagonists |
| WO2008029152A2 (en) | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| US8198438B2 (en) * | 2007-04-18 | 2012-06-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| ES2400604T3 (es) * | 2007-08-17 | 2013-04-11 | Icagen, Inc. | Heterociclos como moduladores del canal de potasio |
| DE102007051762A1 (de) * | 2007-10-30 | 2009-05-07 | Bayer Healthcare Ag | Substituierte Pyrrolotriazine und ihre Verwendung |
| AR077428A1 (es) | 2009-07-29 | 2011-08-24 | Sanofi Aventis | (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos |
| WO2011018894A1 (en) * | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
| TWI488851B (zh) | 2009-09-03 | 2015-06-21 | 必治妥美雅史谷比公司 | 作為鉀離子通道抑制劑之喹唑啉 |
| CN103221412B (zh) | 2010-09-29 | 2015-08-19 | 橘生药品工业株式会社 | (氮杂)中氮茚衍生物及其药物用途 |
| US8921368B2 (en) * | 2011-03-17 | 2014-12-30 | Bristol-Myers Squibb Company | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
| AR085435A1 (es) * | 2011-03-17 | 2013-10-02 | Bristol Myers Squibb Co | Inhibidores de pirrolopiridazina jak3 y su uso para el tratamiento de enfermedades inflamatorias y autoinmunes |
| EP2685982B1 (en) * | 2011-03-17 | 2017-07-05 | Bristol-Myers Squibb Company | Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
| CN103373996A (zh) | 2012-04-20 | 2013-10-30 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的二并环衍生物 |
| AR091402A1 (es) * | 2012-06-11 | 2015-02-04 | Bristol Myers Squibb Co | Profarmacos de acido fosforadimico |
| US9403834B2 (en) | 2013-03-11 | 2016-08-02 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| US9242966B2 (en) | 2013-03-11 | 2016-01-26 | Bristol-Myers Squibb Company | Phthalazines as potassium ion channel inhibitors |
| WO2014143609A1 (en) | 2013-03-11 | 2014-09-18 | Bristol-Myers Squibb Company | Isoquinolines as potassium ion channel inhibitors |
-
2014
- 2014-03-10 JP JP2016500921A patent/JP6386527B2/ja not_active Expired - Fee Related
- 2014-03-10 WO PCT/US2014/022238 patent/WO2014143607A1/en not_active Ceased
- 2014-03-10 ES ES14713002.5T patent/ES2616026T3/es active Active
- 2014-03-10 CN CN201480013610.3A patent/CN105008366B/zh not_active Expired - Fee Related
- 2014-03-10 EP EP14713002.5A patent/EP2970295B1/en not_active Not-in-force
- 2014-03-10 US US14/772,152 patent/US9458164B2/en active Active